Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Wave Life Sciences (WVE) announced positive results from its phase 1b/2a RestorAAtion-2 study using WVE-006 for the treatment of patients with alpha-1 antitrypsin deficiency [AATD]. It was shown that ...
atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant ...
The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results